Literature DB >> 16940061

In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.

Jason Cota1, Michael Carden, John R Graybill, Laura K Najvar, David S Burgess, Nathan P Wiederhold.   

Abstract

The activities of anidulafungin and caspofungin against Candida glabrata were evaluated. MICs, 50% inhibitory concentrations (IC(50) values), and IC(90) values for anidulafungin were lower than those for caspofungin for 16 of 18 strains tested. Anidulafungin has potent in vitro activity against C. glabrata that is maintained against isolates with elevated caspofungin MICs.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16940061      PMCID： PMC1635202          DOI： 10.1128/AAC.00538-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  29 in total

1.  Has antifungal susceptibility testing come of age?

Authors:  John H Rex; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2002-09-24       Impact factor: 9.079

Review 2.  The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy.

Authors:  Nathan P Wiederhold; Russell E Lewis
Journal:  Expert Opin Investig Drugs       Date:  2003-08       Impact factor: 6.206

3.  Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.

Authors:  Morgan Hakki; Janet F Staab; Kieren A Marr
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

4.  Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis [2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide], for antifungal susceptibility testing of Aspergillus species.

Authors:  J Meletiadis; J W Mouton; J F Meis; B A Bouman; P J Donnelly; P E Verweij
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

5.  The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer.

Authors:  Gerald P Bodey; Masoud Mardani; Hend A Hanna; Maha Boktour; Jalal Abbas; Essam Girgawy; Ray Y Hachem; Dimitrios P Kontoyiannis; Issam I Raad
Journal:  Am J Med       Date:  2002-04-01       Impact factor: 4.965

6.  Voriconazole treatment for less-common, emerging, or refractory fungal infections.

Authors:  John R Perfect; Kieren A Marr; Thomas J Walsh; Richard N Greenberg; Bertrand DuPont; Juliàn de la Torre-Cisneros; Gudrun Just-Nübling; Haran T Schlamm; Irja Lutsar; Ana Espinel-Ingroff; Elizabeth Johnson
Journal:  Clin Infect Dis       Date:  2003-04-22       Impact factor: 9.079

7.  Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Peter G Pappas; Richard J Hamill; Robert A Larsen; Harold W Horowitz; William G Powderly; Newton Hyslop; Carol A Kauffman; John Cleary; Julie E Mangino; Jeannette Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

8.  A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

Authors:  Peter G Pappas; John H Rex; Jeannette Lee; Richard J Hamill; Robert A Larsen; William Powderly; Carol A Kauffman; Newton Hyslop; Julie E Mangino; Stanley Chapman; Harold W Horowitz; John E Edwards; William E Dismukes
Journal:  Clin Infect Dis       Date:  2003-08-14       Impact factor: 9.079

9.  Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method.

Authors:  María Pilar Arévalo; Alfonso-Javier Carrillo-Muñoz; Javier Salgado; Delia Cardenes; Sonia Brió; Guillermo Quindós; Ana Espinel-Ingroff
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

10.  Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods.

Authors:  Ellen E Roling; Michael E Klepser; Ashley Wasson; Russell E Lewis; Erika J Ernst; Michael A Pfaller
Journal:  Diagn Microbiol Infect Dis       Date:  2002-05       Impact factor: 2.803
View more
  13 in total

1.  Occidiofungin's chemical stability and in vitro potency against Candida species.

Authors:  Dayna Ellis; Jiten Gosai; Charles Emrick; Rachel Heintz; Lanette Romans; Donna Gordon; Shi-En Lu; Frank Austin; Leif Smith
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

Review 2.  Echinocandin antifungal drugs in fungal infections: a comparison.

Authors:  Sharon C-A Chen; Monica A Slavin; Tania C Sorrell
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

3.  In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera.

Authors:  Nathan P Wiederhold; Laura K Najvar; Rosie Bocanegra; Destiny Molina; Marcos Olivo; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2007-02-16       Impact factor: 5.191

4.  Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans.

Authors:  Nathan P Wiederhold; Laura K Najvar; Rosie A Bocanegra; William R Kirkpatrick; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

5.  Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.

Authors:  George R Thompson; Nathan P Wiederhold; Ana C Vallor; Nyria C Villareal; James S Lewis; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

6.  In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.

Authors:  D R Andes; D J Diekema; M A Pfaller; K Marchillo; J Bohrmueller
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

7.  In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.

Authors:  D Andes; D J Diekema; M A Pfaller; R A Prince; K Marchillo; J Ashbeck; J Hou
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

8.  Increases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofungin.

Authors:  Jason M Cota; Jodi L Grabinski; Robert L Talbert; David S Burgess; P David Rogers; Thomas D Edlind; Nathan P Wiederhold
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

Review 9.  Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature.

Authors:  G Kofla; Markus Ruhnke
Journal:  Eur J Med Res       Date:  2011-04-28       Impact factor: 2.175

10.  Anidulafungin: an evidence-based review of its use in invasive fungal infections.

Authors:  Susan L Davis; Jose A Vazquez
Journal:  Core Evid       Date:  2008-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.